Compare GMGI & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GMGI | SERA |
|---|---|---|
| Founded | 2008 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Precision Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 103.5M | 90.6M |
| IPO Year | N/A | 2021 |
| Metric | GMGI | SERA |
|---|---|---|
| Price | $0.86 | $3.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | ★ 235.8K | 42.6K |
| Earning Date | 10-30-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $179,142,103.00 | $95,000.00 |
| Revenue This Year | $25.59 | $19.22 |
| Revenue Next Year | $14.27 | $400.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 37.24 | 1.06 |
| 52 Week Low | $0.70 | $1.37 |
| 52 Week High | $2.60 | $9.13 |
| Indicator | GMGI | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 50.95 | 60.54 |
| Support Level | $0.74 | $2.91 |
| Resistance Level | $0.84 | $3.14 |
| Average True Range (ATR) | 0.07 | 0.26 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 96.23 | 79.55 |
Golden Matrix Group Inc is an established gaming technology company. The company develops and owns online gaming IP and builds configurable and scalable white-label social gaming platforms for its international customers. The company operates in three reportable segments; MeridianBet Group, GMAG, RKings & CFAC. The MeridianBet Group segment earns majority revenue. The company operates in UK, Europe, Asia Pacific, Central and South America, Australia and Africa. It offers configurable and scalable iGaming platforms and operate some of the industry's iconic brands, including MexPlay, GM-AG, and others.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.